Arivin Therapeutics

Based in Finland, Arvin Therapeutics develops innovative antimicrobial therapies to combat gram-negative infections by targeting bacterial virulence factors and addressing the critical challenge of antibiotic resistance. Arvin Therapeutics, established in Helsinki, Finland, focuses on developing antimicrobial therapies. The company has completed 1 deal, with its most recent deal occurring on September 2, 2025, during its SEED funding round, where it raised EUR 3 million from investors including Business Finland Venture Capital. The founder's details are currently not available.

Arvin Therapeutics specializes in developing antimicrobial therapies aimed at combating gram-negative infections by neutralizing lethal bacterial toxins and disrupting biofilm formation. The products are intended for healthcare providers, such as hospitals and clinics, primarily in North America and Europe, serving infectious disease specialists and healthcare organizations facing antibiotic resistance challenges. Arvin Therapeutics generates revenue through partnerships with healthcare institutions and potential licensing agreements for its proprietary therapies. Its B2B transaction structure targets hospitals and clinics seeking effective treatments for resistant bacterial infections, relying on upfront payments, milestone payments, and royalties on product sales.

In September 2025, Arvin Therapeutics raised EUR 3 million in SEED funding to accelerate clinical research and expand its team and operations. The company plans to develop new antimicrobial products and is targeting expansion into North America and Europe. The funding will support the clinical development process and broaden operational capabilities.